Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study
Objective: To evaluate the effects of cinpanemab on biomarkers in participants with Parkinson’s disease (PD). Background: SPARK (NCT03318523) was designed to evaluate the safety, pharmacokinetics,…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease
Objective: Report outcomes from Part 2 of the phase 2 MOVES-PD trial (NCT02906020) in patients with PD stratified by glucocerebrosidase (GBA) gene mutation severity. Background:…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study
Objective: Analyze the impact of levodopa-carbidopa intestinal gel (LCIG) treatment on dyskinesia duration and severity in advanced Parkinson’s disease (APD) patients participating in the COSMOS…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat
Objective: To assess the effect of LY-404,039 on dyskinesia and parkinsonism in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD). Background: LY-404,039 is an…Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study
Objective: This study aimed to explore patients’ adherence to antiparkinsonian medication, and to determine factors associated with low adherence among Serbian PD patients. Background: Adherence…Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study
Objective: This post-hoc analysis evaluated the effects of opicapone (OPC) treatment in patients with Parkinson’s disease (PD) who experience motor fluctuations and complications of therapy…Wearable sensor motor outcomes across patients with Parkinson’s disease from Asian, Black, and Caucasian ethnicity in the United Kingdom
Objective: To determine the effect of ethnic background on motor scores in people with Parkinson’s disease (PwP) using objective measurement. Background: Limited evidence has suggested…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 132
- Next Page »